Kanvas Biosciences is building the world's first microbiome drug screening and drug discovery platform to accelerate live biotherapeutic product (LBP) development. Leveraging its unparalleled ability to spatially map the microbiome and profile host-gene expression at single-cell resolution, the company is constructing the most comprehensive and robust microbiome data resource for future drug development. Kanvas Biosciences' technology was initially developed at Cornell University and exclusively licensed.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/22/23 | $12,000,000 | Pre-Series A |
Cooke LLC DCVC  Lions Capital Triple Impact Capital Uncommon Denominator | undisclosed |
